C1q/tumor necrosis factor (TNF)-related proteins (CTRPs) have been linked to energy homeostasis and vascular health. People with HIV are susceptible to cardiometabolic disease, but the contributions of different CTRPs are unknown. We investigated the associations of HIV and related factors with serum CTRPs, and CTRPs' relationships with cardiometabolic phenotypes. This involved a cross-sectional analysis of participants in the Women's Interagency HIV Study aged ≥35 with (n = 209) and without (n = 92) HIV who underwent carotid ultrasound in 2004–2005 and had stored serum available for measurement of total adiponectin and CTRPs 1, 3, 5, and 9. The Benjamini/Hochberg procedure was used to control the study-wide false-positive rate. HIV-positive women had significantly higher adiponectin than HIV-negative women after adjustment for sociodemographic, behavioral, and clinical variables [beta = 0.29 (95% confidence interval 0.11–0.47)]. Among HIV-positive women, lower CD4 count was associated with higher adiponectin and history of AIDS with higher CTRP9, but these were only nominally significant. There was no relationship between HIV status and CTRP 1, 3, or 5, nor was antiretroviral therapy or viral load associated with any CTRP. In the entire cohort, higher adiponectin was associated with significantly lower fasting glucose and insulin resistance, while higher CTRP5 [beta = -0.02 (−0.033 to −0.007)]—and, at a nominal level, CTRPs 1 and 3—was associated with significantly lower carotid intima-media thickness. In conclusion, in this sample of middle-aged women, HIV serostatus was positively associated with adiponectin, but not CTRPs. In turn, serum adiponectin was inversely associated with glucose dysregulation, whereas CTRP5 was inversely associated with carotid intima-media thickness. Further research is needed to determine CTRPs' role in atherosclerosis.
Get full access to this article
View all access options for this article.
References
1.
KizerJR: Adiponectin, cardiovascular disease, and mortality: Parsing the dual prognostic implications of a complex adipokine. Metabolism, 2014; 63:1079–1083.
2.
KizerJR, BenkeserD, ArnoldAM, et al.: Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J Clin Endocrinol Metab, 2013; 98:255–263.
3.
KizerJR, BenkeserD, ArnoldAM, et al.: Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: The Cardiovascular Health Study. Circulation, 2012; 126:2951–2961.
4.
LicinioJ, CaglayanS, OzataM, et al.: Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A, 2004; 101:4531–4536.
5.
WongGW, KrawczykSA, Kitidis-MitrokostasC, RevettT, GimenoR, LodishHF: Molecular, biochemical and functional characterizations of C1q/TNF family members: Adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J, 2008; 416:161–177.
6.
WongGW, KrawczykSA, Kitidis-MitrokostasC, et al.: Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J, 2009; 23:241–258.
7.
ZhengQ, YuanY, YiW, et al.: C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler Thromb Vasc Biol, 2011; 31:2616–2623.
8.
KoppA, BalaM, BuechlerC, et al.: C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology, 2010; 151:5267–5278.
9.
PetersonJM, WeiZ, WongGW: C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. J Biol Chem, 2010; 285:39691–39701.
10.
HanS, ParkJS, LeeS, et al.: CTRP1 protects against diet-induced hyperglycemia by enhancing glycolysis and fatty acid oxidation. J Nutr Biochem, 2016; 27:43–52.
11.
PetersonJM, AjaS, WeiZ, WongGW: CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. J Biol Chem, 2012; 287:1576–1587.
12.
KanemuraN, ShibataR, OhashiK, et al.: C1q/TNF-related protein 1 prevents neointimal formation after arterial injury. Atherosclerosis, 2017; 257:138–145.
13.
LuL, ZhangRY, WangXQ, et al.: C1q/TNF-related protein-1: An adipokine marking and promoting atherosclerosis. Eur Heart J, 2016; 37:1762–1771.
14.
WangXQ, LiuZH, XueL, et al.: C1q/TNF-related protein 1 links macrophage lipid metabolism to inflammation and atherosclerosis. Atherosclerosis, 2016; 250:38–45.
15.
LeiX, RodriguezS, PetersenPS, et al.: Loss of CTRP5 improves insulin action and hepatic steatosis. Am J Physiol Endocrinol Metab, 2016; 310:E1036–E1052.
16.
SeldinMM, TanSY, WongGW: Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord, 2014; 15:111–123.
17.
KaplanRC, HannaDB, KizerJR: Recent insights into cardiovascular disease (CVD) risk among HIV-infected adults. Curr HIV/AIDS Rep, 2016; 13:44–52.
18.
HadiganC, KattakuzhyS: Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am, 2014; 43:685–696.
19.
TillersonK: Explaining racial disparities in HIV/AIDS incidence among women in theU.S.: A systematic review. Stat Med, 2008; 27:4132–4143.
20.
LiuL, NunezAE, AnY, et al.: Burden of cardiovascular disease among multi-racial and ethnic populations in the United States: An update from the National Health Interview Surveys. Front Cardiovasc Med, 2014; 1:8.
21.
KetlogetsweKS, PostWS, LiX, et al.: Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men. AIDS, 2014; 28:901–909.
22.
FreitasP, CarvalhoD, SantosAC, et al.: Adipokines, hormones related to body composition, and insulin resistance in HIV fat redistribution syndrome. BMC Infect Dis, 2014; 14:347.
23.
KosmiskiLA, BacchettiP, KotlerDP, et al.: Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab, 2008; 93:216–224.
24.
AddyCL, GavrilaA, TsiodrasS, BrodoviczK, KarchmerAW, MantzorosCS: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab, 2003; 88:627–636.
25.
TongQ, SankaleJL, HadiganCM, et al.: Regulation of adiponectin in human immunodeficiency virus-infected patients: Relationship to body composition and metabolic indices. J Clin Endocrinol Metab, 2003; 88:1559–1564.
26.
DolanSE, HadiganC, KillileaKM, et al.: Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr, 2005; 39:44–54.
27.
SharmaA, MaY, ScherzerR, et al.: Brief report: Association of adipokines with bone mineral density in HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr, 2016; 73:433–437.
28.
BaconMC, von WylV, AldenC, et al.: The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol, 2005; 12:1013–1019.
29.
KaplanRC, KingsleyLA, GangeSJ, et al.: Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS, 2008; 22:1615–1624.
30.
MatthewsDR, HoskerJP, RudenskiAS, NaylorBA, TreacherDF, TurnerRC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
31.
HodisHN, MackWJ, LoboRA, et al.: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2001; 135:939–953.
32.
SeabergEC, BenningL, SharrettAR, et al.: Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke, 2010; 41:2163–2170.
33.
SelzerRH, MackWJ, LeePL, Kwong-FuH, HodisHN: Improved common carotid elasticity and intima-media thickness measurements from computer analysis of sequential ultrasound frames. Atherosclerosis, 2001; 154:185–193.
34.
TienPC, SchneiderMF, CoxC, et al.: Association of HIV infection with incident diabetes mellitus: Impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr, 2012; 61:334–340.
35.
LeveyAS, StevensLA, SchmidCH, et al.: A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009; 150:604–612.
36.
KullerLH, TracyR, BellosoW, et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med, 2008; 5:e203.
37.
HuckDM, HannaDB, RubinLH, et al.: Carotid artery stiffness and cognitive decline among women with or at risk for HIV infection. J Acquir Immune Defic Syndr, 2018; 78:338–347.
38.
WolfRM, SteeleKE, PetersonLA, et al.: C1q/TNF-related protein-9 (CTRP9) levels are associated with obesity and decrease following weight loss surgery. J Clin Endocrinol Metab, 2016; 101:2211–2217.
39.
HwangYC, Woo OhS, ParkSW, ParkCY: Association of serum C1q/TNF-related protein-9 (CTRP9) concentration with visceral adiposity and metabolic syndrome in humans. Int J Obes (Lond), 2014; 38:1207–1212.
40.
MoradiN, FadaeiR, EmamgholipourS, et al.: Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease. PLoS One, 2018; 13:e0192159.
41.
SchwartzeJT, LandgrafK, SpielauU, et al.: Adipocyte C1QTNF5 expression is BMI-dependently related to early adipose tissue dysfunction and systemic CTRP5 serum levels in obese children. Int J Obes (Lond), 2017; 41:955–963.
42.
ShenY, LiC, ZhangRY, et al.: Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells. Int J Cardiol, 2017; 228:129–136.
43.
LasserG, GuchhaitP, EllsworthJL, et al.: C1qTNF-related protein-1 (CTRP-1): A vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood, 2006; 107:423–430.
44.
WangS, LingY, LiangW, ShenL: Association of serum C1q/TNF-related protein-3 (CTRP-3) in patients with coronary artery disease. BMC Cardiovasc Disord, 2017; 17:210.
45.
FadaeiR, MoradiN, BaratchianM, et al.: Association of C1q/TNF-related protein-3 (CTRP3) and CTRP13 serum levels with coronary artery disease in subjects with and without type 2 diabetes mellitus. PLoS One, 2016; 11:e0168773.
46.
BotsML, HoesAW, KoudstaalPJ, HofmanA, GrobbeeDE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation, 1997; 96:1432–1437.
47.
LorenzMW, MarkusHS, BotsML, RosvallM, SitzerM: Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation, 2007; 115:459–467.
48.
EikendalAL, GroenewegenKA, AndersonTJ, et al.: Common carotid intima-media thickness relates to cardiovascular events in adults aged <45 years. Hypertension, 2015; 65:707–713.
49.
SakkinenP, AbbottRD, CurbJD, RodriguezBL, YanoK, TracyRP: C-reactive protein and myocardial infarction. J Clin Epidemiol, 2002; 55:445–451.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
